Jan 30 (Reuters) – CSPC Pharmaceutical Group said on Friday it had entered an agreement with UK drugmaker AstraZeneca for the development of innovative long-acting peptide medicines for obesity and weight-related conditions.
AstraZeneca will obtain access to some of the programmes and platforms of the Chinese biotechnology firm’s pharmaceutical in exchange for an upfront payment of $1.2 billion, it added.
(Reporting by Sherin Sunny in Bengaluru; Editing by Rashmi Aich)
